Agaeva R A, Danilov N M, Shelkova G V, Matchin Y G, Chazova I E
Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology.
Ter Arkh. 2020 Jul 9;92(6):84-88. doi: 10.26442/00403660.2020.06.000588.
Radiofrequency renal artery denervation (RND) was introduced as a method of interventional treatment of resistant hypertension almost ten years ago. The first studies demonstrated the effectiveness of this procedure. This has led to growing interest in this area and the rapid development of the method. However, the results of the first randomized trial of SYMPLICITY HTN-3 questioned the role of RND in the treatment of resistant hypertension, this fact conducted to the decrease in the recommendation class and level of evidence in the Guidelines of the European Society of Cardiology and the European Society of Hypertension in 2018. To date, the medical community is actively discussing the results of recently published trials such as SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED, RADIANCE-HTN SOLO and RADIOSOUND-HTN.
射频肾动脉去神经支配术(RND)大约在十年前作为一种顽固性高血压的介入治疗方法被引入。最初的研究证明了该手术的有效性。这引发了对该领域越来越浓厚的兴趣以及该方法的快速发展。然而,SYMPLICITY HTN - 3的首个随机试验结果对RND在顽固性高血压治疗中的作用提出了质疑,这一事实导致在2018年欧洲心脏病学会和欧洲高血压学会的指南中,推荐等级和证据水平有所降低。迄今为止,医学界正在积极讨论最近发表的试验结果,如SPYRAL HTN - OFF MED、SPYRAL HTN - ON MED、RADIANCE - HTN SOLO和RADIOSOUND - HTN。